<DOC>
	<DOCNO>NCT02327442</DOCNO>
	<brief_summary>The purpose study assess safety , biodistribution , dosimetric property positron emission tomography ( PET ) radiopharmaceutical agent 68Ga-NOTA-NFB . To preliminarily evaluate application glioma diagnosis . To assess application 68Ga-NOTA-NFB PET/CT evaluation neoadjuvant chemotherapy patient breast cancer therapy .</brief_summary>
	<brief_title>68Ga-NOTA-NFB : Radiation Dosimetry Healthy Volunteers Applications Glioma Patients Breast Cancer Patients</brief_title>
	<detailed_description>6 healthy volunteer whole-body PET/CT scan 0 , 0.5 , 1.0 , 2.0 , 3.0 hour tracer injection ( mean dose , 4.93 Â± 0.10 mCi ) perform . During imaging period , 1 mL blood sample obtain specifically 1 , 3 , 5 , 10 , 30,60 , 90 , 120 , 150 , 180 minute injection , time-activity curve calculation . The estimated radiation dos calculate use OLINDA/EXM software . 8-10 patient glioma enrol clinical study diagnose glioma , perform 68Ga-NOTA-NFB PET/CT and18F-FDG PET/CT scan surgery . The preoperative image compare correlate pathologically report . Next , expression CXCR4 determine immunohistochemical staining resect brain tumor tissue . 30 patient breast cancer underwent 68Ga-NOTA-NFB PET/CT and18F-FDG PET/CT scan neoadjuvant chemotherapy . SUV lesion therapy contrast .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<criteria>volunteer : healthy patient glioma : diagnose MR ready surgery patient breast : cancer appropritate neoadjuvant chemotherapy . patient glioma : refuse endure surgery . patient breast : refuse neoadjuvant chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>chemokine receptor</keyword>
	<keyword>galium</keyword>
	<keyword>dosimetry</keyword>
	<keyword>glioma</keyword>
</DOC>